Bo Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bo Wei has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Lijun Song
Affiliation Reproductive Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
4 shared publications - Sien Lin
Department of Orthopaedics and Traumatology, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
4 shared publications Zeyu Zhan
Affiliation Orthopedics Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
4 shared publicationsHang Wu
Affiliation Orthopedics Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
3 shared publicationsHe Pang
Orthopedics Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China
3 shared publicationsTingrui Wu
Orthopedics Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
3 shared publications
Latest Publications
- Open Access
- 11 April 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 27 (1)
Biomechanical effects of a novel anatomic fusion cage for anterior cervical corpectomy: a finite element study
Background: Anterior cervical corpectomy and fusion (ACCF) is a crucial surgical procedure for addressing cervical degenerative diseases. However, traditional titanium mesh cages (TTMC) are susceptible to complications, such as cage subsidence and internal fixation failure. In this study, we developed a novel anatomic titanium mesh cage (NATMC) and assessed its biomechanical properties through finite element analysis. Methods: A conventional three-dimensional finite element model comprising cervical vertebrae C2–C7 was established using computed tomography (CT) data. Subsequently, two surgical models (TTMC and NATMC) were generated based on the normal model. Uniform load conditions were applied to these distinct surgical models to simulate flexion, extension, lateral bending, and axial rotation of the cervical spine. The range of motion (ROM), stress peaks at the titanium mesh-endplate interface, screw–bone interface, and the adjacent intervertebral disc were recorded and compared between the two groups. Results: In comparison to the intact model, the surgical segmental range of motion (ROM) for C4-6 was reduced by 96.89% in NATMC and 96.91% in TTMC. The stress peaks at the C4 inferior endplate and C6 superior endplate were higher in TTMC, measuring between 1.61 and 9.96 MPa and 1.46–14.29 MPa, respectively, followed by NATMC with values of 0.93–7.75 MPa and 1.08–11.69 MPa. Stress peaks on NATMC were lower (68.47–309.90 MPa) compared to TTMC (86.80–368.30 MPa). Regarding stress peaks at the screw-bone interface, NATMC exhibited lower values (11.91–42.49 MPa) compared to TTMC (35.49–153.00 MPa). Finally, comparing stress peaks in adjacent discs (C3/4 and C6/7), NATMC and TTMC showed similar results, ranging between 1.56 and 5.47 MPa in C3/4 and 1.56–2.91 MPa in C6/7, respectively. Conclusions: The novel anatomic titanium mesh cage demonstrated effective reduction in vertebral subsidence and minimized pressure on the internal fixation interface following anterior cervical corpectomy and fusion (ACCF). It demonstrated superior stability and safety compared to traditional titanium mesh cage.
- 11 April 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 27 (1)
Open AccessBiomechanical effects of a novel anatomic fusion cage for anterior cervical corpectomy: a finite element study
Background: Anterior cervical corpectomy and fusion (ACCF) is a crucial surgical procedure for addressing cervical degenerative diseases. However, traditional titanium mesh cages (TTMC) are susceptible to complications, such as cage subsidence and internal fixation failure. In this study, we developed a novel anatomic titanium mesh cage (NATMC) and assessed its biomechanical properties through finite element analysis. Methods: A conventional three-dimensional finite element model comprising cervical vertebrae C2–C7 was established using computed tomography (CT) data. Subsequently, two surgical models (TTMC and NATMC) were generated based on the normal model. Uniform load conditions were applied to these distinct surgical models to simulate flexion, extension, lateral bending, and axial rotation of the cervical spine. The range of motion (ROM), stress peaks at the titanium mesh-endplate interface, screw–bone interface, and the adjacent intervertebral disc were recorded and compared between the two groups. Results: In comparison to the intact model, the surgical segmental range of motion (ROM) for C4-6 was reduced by 96.89% in NATMC and 96.91% in TTMC. The stress peaks at the C4 inferior endplate and C6 superior endplate were higher in TTMC, measuring between 1.61 and 9.96 MPa and 1.46–14.29 MPa, respectively, followed by NATMC with values of 0.93–7.75 MPa and 1.08–11.69 MPa. Stress peaks on NATMC were lower (68.47–309.90 MPa) compared to TTMC (86.80–368.30 MPa). Regarding stress peaks at the screw-bone interface, NATMC exhibited lower values (11.91–42.49 MPa) compared to TTMC (35.49–153.00 MPa). Finally, comparing stress peaks in adjacent discs (C3/4 and C6/7), NATMC and TTMC showed similar results, ranging between 1.56 and 5.47 MPa in C3/4 and 1.56–2.91 MPa in C6/7, respectively. Conclusions: The novel anatomic titanium mesh cage demonstrated effective reduction in vertebral subsidence and minimized pressure on the internal fixation interface following anterior cervical corpectomy and fusion (ACCF). It demonstrated superior stability and safety compared to traditional titanium mesh cage.
- Open Access
- 11 December 2025
- Published by Springer Nature in Research Square
APLP2 as a Molecular Link Between Immune Regulation and Bone Metabolism in Hepatocellular Carcinoma: Evidence from scRNA-Seq and Functional Validation
Background and Aims: Hepatocellular carcinoma (HCC) remains a significant health concern worldwide, characterized by elevated mortality rates that are often associated with diagnoses occurring in advanced stages and the restricted efficacy of treatment options currently available. Immune checkpoint inhibitors (ICIs) demonstrate promise in treating HCC; nonetheless, challenges related to therapeutic resistance and varied responses among patients underscore the necessity of identifying new biomarkers and comprehending the fundamental mechanisms involved. This research explores the molecular relationship between immune regulation and bone metabolism in HCC by employing integrated single-cell RNA sequencing (scRNA-seq), bulk transcriptomics, and functional validation. Methods: The analysis of publicly accessible scRNA-seq (GSE223204) and bulk RNA-seq (TCGA-LIHC) datasets was conducted to discover distinct cell subpopulations and signaling patterns. Clustering, ligand-receptor interaction analysis, and transcription factor mapping were performed using the Seurat, CellChat, and SCENIC pipelines. A random survival forest method helped identify important prognostic genes. The research examined how immune cells infiltrate and their relationship with components that regulate the immune response. Clinical HCC samples were obtained for validation using qPCR. The functional effects of the gene APLP2 were studied through small interfering RNA (siRNA) knockdown experiments in HCC cell lines and co-culturing with osteoblasts. Results: In the tissues of HCC, nine distinct cell types were recognized, where hepatocytes demonstrated significant involvement in pathways related to bone metabolism and immune functions. Seven key genes (APLP2, SERPINC1, CAT, PDIA6, SLC2A2, C1S, and CFB) were found to be prognostically significant and closely linked to immune cell infiltration, immunomodulatory checkpoints, and key metabolic signaling pathways, including WNT/β-catenin and PI3K-AKT-mTOR. Particularly, APLP2 showed increased expression specifically in cancerous tissues. Reduced APLP2 levels suppressed proliferation, invasion, migration, and promoted apoptosis in HCC cells. Moreover, the downregulation of APLP2 lessened the suppressive influence of tumor cells on osteoblast differentiation, indicating its potential regulatory function in bone metabolism. Conclusion: This research highlights APLP2 as a new molecular connector between immune evasion and dysregulation of bone metabolism in HCC. The combination of single-cell analysis along with experimental validation offers fresh perspectives on the underlying mechanisms of immunotherapy resistance and emphasizes APLP2 as a promising dual-function therapeutic target.
- 11 December 2025
- Published by Springer Nature in Research Square
Open AccessAPLP2 as a Molecular Link Between Immune Regulation and Bone Metabolism in Hepatocellular Carcinoma: Evidence from scRNA-Seq and Functional Validation
Background and Aims: Hepatocellular carcinoma (HCC) remains a significant health concern worldwide, characterized by elevated mortality rates that are often associated with diagnoses occurring in advanced stages and the restricted efficacy of treatment options currently available. Immune checkpoint inhibitors (ICIs) demonstrate promise in treating HCC; nonetheless, challenges related to therapeutic resistance and varied responses among patients underscore the necessity of identifying new biomarkers and comprehending the fundamental mechanisms involved. This research explores the molecular relationship between immune regulation and bone metabolism in HCC by employing integrated single-cell RNA sequencing (scRNA-seq), bulk transcriptomics, and functional validation. Methods: The analysis of publicly accessible scRNA-seq (GSE223204) and bulk RNA-seq (TCGA-LIHC) datasets was conducted to discover distinct cell subpopulations and signaling patterns. Clustering, ligand-receptor interaction analysis, and transcription factor mapping were performed using the Seurat, CellChat, and SCENIC pipelines. A random survival forest method helped identify important prognostic genes. The research examined how immune cells infiltrate and their relationship with components that regulate the immune response. Clinical HCC samples were obtained for validation using qPCR. The functional effects of the gene APLP2 were studied through small interfering RNA (siRNA) knockdown experiments in HCC cell lines and co-culturing with osteoblasts. Results: In the tissues of HCC, nine distinct cell types were recognized, where hepatocytes demonstrated significant involvement in pathways related to bone metabolism and immune functions. Seven key genes (APLP2, SERPINC1, CAT, PDIA6, SLC2A2, C1S, and CFB) were found to be prognostically significant and closely linked to immune cell infiltration, immunomodulatory checkpoints, and key metabolic signaling pathways, including WNT/β-catenin and PI3K-AKT-mTOR. Particularly, APLP2 showed increased expression specifically in cancerous tissues. Reduced APLP2 levels suppressed proliferation, invasion, migration, and promoted apoptosis in HCC cells. Moreover, the downregulation of APLP2 lessened the suppressive influence of tumor cells on osteoblast differentiation, indicating its potential regulatory function in bone metabolism. Conclusion: This research highlights APLP2 as a new molecular connector between immune evasion and dysregulation of bone metabolism in HCC. The combination of single-cell analysis along with experimental validation offers fresh perspectives on the underlying mechanisms of immunotherapy resistance and emphasizes APLP2 as a promising dual-function therapeutic target.
- Open Access
- 24 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0332202
Investigating the anti-osteosarcoma effects of Patchouli alcohol through protein network mapping and in vitro experiments
Osteosarcoma is one of the most common malignant tumors in orthopedics, especially in the metaphysis of tubular bones of the extremities in adolescents. Patchouli alcohol (PA) is a tricyclic sesquiterpene isolated from Patchouli, a Labiatae family, which has been shown to have antitumor efficacy against a variety of cancers. However, the effects and mechanisms of PA against osteosarcoma remain to be elucidated. Sixty-three possible therapeutic targets of PA against osteosarcoma were identified by protein network mapping analysis. PPI network analysis and KEGG functional enrichment analysis showed that PA exerts significant therapeutic effects on osteosarcoma through multiple targets and pathways, especially the PI3K/Akt pathway. Molecular docking results indicated that PA had significant binding to EGFR, HSP90AA1, ESR1 and SRC targets. In vitro experiments, PA inhibited proliferation and induced G2/M arrest in osteosarcoma cells in a dose- and time-dependent manner. PA induced apoptosis in osteosarcoma cells through a decrease in mitochondrial membrane potential. Alterations in the expression of apoptosis-related proteins Bcl-2 and Bax also confirmed that PA promoted apoptosis in osteosarcoma cells. Treatment with PA promoted more autophagosome formation, increased autophagy-related protein LC3-II/I ratio as well as decreased p62 expression in osteosarcoma cells. In addition, PA decreased the expression of p-PI3K/PI3K, and p-Akt/Akt in osteosarcoma cells. These findings indicated that PA exerts anti-osteosarcoma effects by inhibiting osteosarcoma cell proliferation, inducing apoptosis, promoting autophagy and inhibiting PI3K/Akt pathway, suggesting PA as a potential agent against osteosarcoma.
- 24 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0332202
Open AccessInvestigating the anti-osteosarcoma effects of Patchouli alcohol through protein network mapping and in vitro experiments
Osteosarcoma is one of the most common malignant tumors in orthopedics, especially in the metaphysis of tubular bones of the extremities in adolescents. Patchouli alcohol (PA) is a tricyclic sesquiterpene isolated from Patchouli, a Labiatae family, which has been shown to have antitumor efficacy against a variety of cancers. However, the effects and mechanisms of PA against osteosarcoma remain to be elucidated. Sixty-three possible therapeutic targets of PA against osteosarcoma were identified by protein network mapping analysis. PPI network analysis and KEGG functional enrichment analysis showed that PA exerts significant therapeutic effects on osteosarcoma through multiple targets and pathways, especially the PI3K/Akt pathway. Molecular docking results indicated that PA had significant binding to EGFR, HSP90AA1, ESR1 and SRC targets. In vitro experiments, PA inhibited proliferation and induced G2/M arrest in osteosarcoma cells in a dose- and time-dependent manner. PA induced apoptosis in osteosarcoma cells through a decrease in mitochondrial membrane potential. Alterations in the expression of apoptosis-related proteins Bcl-2 and Bax also confirmed that PA promoted apoptosis in osteosarcoma cells. Treatment with PA promoted more autophagosome formation, increased autophagy-related protein LC3-II/I ratio as well as decreased p62 expression in osteosarcoma cells. In addition, PA decreased the expression of p-PI3K/PI3K, and p-Akt/Akt in osteosarcoma cells. These findings indicated that PA exerts anti-osteosarcoma effects by inhibiting osteosarcoma cell proliferation, inducing apoptosis, promoting autophagy and inhibiting PI3K/Akt pathway, suggesting PA as a potential agent against osteosarcoma.
- Open Access
- 19 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0309951
Mechanism of MiR-145a-3p/Runx2 pathway in dexamethasone impairment of MC3T3-E1 osteogenic capacity in mice
Objective: In this experiment, we screened key miRNAs involved in the dexamethasone-induced decrease in osteogenic capacity of mouse precursor osteoblasts MC3T3-E1 over and investigated their specific regulatory mechanisms. Methods: In this experiment, cell counting kit assay was utilized to act on MC3T3-E1 cells at 0, 5μM, 10μM, 15μM concentrations of dexamethasone for 24h, 48h and 72h to observe the changes in cell viability in order to select the appropriate dexamethasone concentration. Apoptosis and reactive oxygen species were detected by flow cytometry. The transcription of osteogenesis-related genes (Runx2, ALP, OCN, OPN, OPG, COL1A1) and protein expression levels (Runx2, ALP, OCN, OPN) were detected by Western Blot and qRT-PCR to validate the changes in cellular osteogenesis. The differentially expressed miRNAs related to MC3T3-E1 osteogenic differentiation after dexamethasone action were screened out. The expression levels of selected target miRNAs were verified in the experimental group and the control group by qRT-PCR. The miRNA inhibitor was transfected to knock down miRNA in dexamethasone-induced MC3T3-E1 injury. Alkaline phosphatase staining and flow cytometry were performed to detect apoptosis and reactive oxygen species changes. transcript and protein expression levels of osteogenesis-related genes in mouse MC3T3-E1 were detected by qRT-PCR and Western blot experiments. By miRNA target gene prediction, luciferase reporter gene experiments, qRT-PCR and Western blot experiments were used to verify whether the selected target miRNAs targeted the target gene. Results: First, it was determined that 10μM dexamethasone solution was effective in inducing a decrease in osteogenic function in mouse MC3T3-E1 by CCK8 experiments, which showed a significant decrease in alkaline phosphatase activity, a decrease in calcium nodules as shown by alizarin red staining, an increase in apoptosis and reactive oxygen species as detected by flow cytometry, as well as a decrease in the expression of osteogenesis-related genes and proteins. Five target miRNAs were identified: miR-706, miR-296-3p, miR-7011-5p, miR-145a-3p, and miR-149-3p. miR-145a-3p, which had the most pronounced and stable expression trend and was the most highly expressed miRNA, was chosen as the target of this experiment by qRT-PCR analysis. -145a-3p, as the subject of this experiment. Knockdown of miR-145a-3p in MC3T3-E1 cells after dexamethasone action significantly improved the expression of their impaired osteogenic indicators. It was shown that after knocking down the target miRNA, alkaline phosphatase staining was significantly increased compared with the dexamethasone-stimulated group and approached the level of the blank control group. Meanwhile, the expression of osteogenic function-related proteins and genes also increased in the dexamethasone-stimulated group after knocking down miR-145a-3p, and approached the level of the blank control group. A direct targeting relationship between miR-145a-3p and Runx2 was indeed confirmed by luciferase reporter gene assays, qRT-PCR and Western blot experiments. Conclusions: The results indicated that dexamethasone impaired the osteogenic differentiation ability of MC3T3-E1 cells by inducing the up-regulation of miR-145a-3p expression. MiR-145a-3p inhibited the osteogenic differentiation ability of MC3T3-E1 cells by targeting and suppressing the expression level of Runx2 protein. Inhibition of miR-145a-3p levels significantly improved the osteogenic differentiation ability of MC3T3-E1 cells.
- 19 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0309951
Open AccessMechanism of MiR-145a-3p/Runx2 pathway in dexamethasone impairment of MC3T3-E1 osteogenic capacity in mice
Objective: In this experiment, we screened key miRNAs involved in the dexamethasone-induced decrease in osteogenic capacity of mouse precursor osteoblasts MC3T3-E1 over and investigated their specific regulatory mechanisms. Methods: In this experiment, cell counting kit assay was utilized to act on MC3T3-E1 cells at 0, 5μM, 10μM, 15μM concentrations of dexamethasone for 24h, 48h and 72h to observe the changes in cell viability in order to select the appropriate dexamethasone concentration. Apoptosis and reactive oxygen species were detected by flow cytometry. The transcription of osteogenesis-related genes (Runx2, ALP, OCN, OPN, OPG, COL1A1) and protein expression levels (Runx2, ALP, OCN, OPN) were detected by Western Blot and qRT-PCR to validate the changes in cellular osteogenesis. The differentially expressed miRNAs related to MC3T3-E1 osteogenic differentiation after dexamethasone action were screened out. The expression levels of selected target miRNAs were verified in the experimental group and the control group by qRT-PCR. The miRNA inhibitor was transfected to knock down miRNA in dexamethasone-induced MC3T3-E1 injury. Alkaline phosphatase staining and flow cytometry were performed to detect apoptosis and reactive oxygen species changes. transcript and protein expression levels of osteogenesis-related genes in mouse MC3T3-E1 were detected by qRT-PCR and Western blot experiments. By miRNA target gene prediction, luciferase reporter gene experiments, qRT-PCR and Western blot experiments were used to verify whether the selected target miRNAs targeted the target gene. Results: First, it was determined that 10μM dexamethasone solution was effective in inducing a decrease in osteogenic function in mouse MC3T3-E1 by CCK8 experiments, which showed a significant decrease in alkaline phosphatase activity, a decrease in calcium nodules as shown by alizarin red staining, an increase in apoptosis and reactive oxygen species as detected by flow cytometry, as well as a decrease in the expression of osteogenesis-related genes and proteins. Five target miRNAs were identified: miR-706, miR-296-3p, miR-7011-5p, miR-145a-3p, and miR-149-3p. miR-145a-3p, which had the most pronounced and stable expression trend and was the most highly expressed miRNA, was chosen as the target of this experiment by qRT-PCR analysis. -145a-3p, as the subject of this experiment. Knockdown of miR-145a-3p in MC3T3-E1 cells after dexamethasone action significantly improved the expression of their impaired osteogenic indicators. It was shown that after knocking down the target miRNA, alkaline phosphatase staining was significantly increased compared with the dexamethasone-stimulated group and approached the level of the blank control group. Meanwhile, the expression of osteogenic function-related proteins and genes also increased in the dexamethasone-stimulated group after knocking down miR-145a-3p, and approached the level of the blank control group. A direct targeting relationship between miR-145a-3p and Runx2 was indeed confirmed by luciferase reporter gene assays, qRT-PCR and Western blot experiments. Conclusions: The results indicated that dexamethasone impaired the osteogenic differentiation ability of MC3T3-E1 cells by inducing the up-regulation of miR-145a-3p expression. MiR-145a-3p inhibited the osteogenic differentiation ability of MC3T3-E1 cells by targeting and suppressing the expression level of Runx2 protein. Inhibition of miR-145a-3p levels significantly improved the osteogenic differentiation ability of MC3T3-E1 cells.
- 16 September 2024
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 42 (12) , 1055-1069
Metformin acts on miR-181a-5p/PAI-1 axis in stem cells providing new strategies for improving age-related osteogenic differentiation decline
A general decline in the osteogenic differentiation capacity of human bone marrow mesenchymal stem cells (hBMSCs) in the elderly is a clinical consensus, with diverse opinions on the mechanisms. Many studies have demonstrated that metformin (MF) significantly protects against osteoporosis and reduces fracture risk. However, the exact mechanism of this effect remains unclear. In this study, we found that the decreased miR-181a-5p expression triggered by MF treatment plays a critical role in recovering the osteogenic ability of aging hBMSCs (derived from elderly individuals). Notably, the miR-181a-5p expression in hBMSCs was significantly decreased with prolonged MF (1000 μM) treatment. Further investigation revealed that miR-181a-5p overexpression markedly impairs the osteogenic ability of hBMSCs, while miR-181a-5p inhibition reveals the opposite result. We also found that miR-181a-5p could suppress the protein translation process of plasminogen activator inhibitor-1 (PAI-1), as evidenced by luciferase assays and Western blots. Additionally, low PAI-1 levels were associated with diminished osteogenic ability, whereas high levels promoted it. These findings were further validated in human umbilical cord mesenchymal stem cells (hUCMSCs). Finally, our in vivo experiment with a bone defects rat model confirmed that the agomiR-181a-5p (long-lasting miR-181a-5p mimic) undermined bone defects recovery, while the antagomiR-181a-5p (long-lasting miR-181a-5p inhibitor) significantly promoted the bone defects recovery. In conclusion, we found that MF promotes bone tissue regeneration through the miR-181a-5p/PAI-1 axis by affecting MSC osteogenic ability, providing new strategies for the treatment of age-related bone regeneration disorders.
- 16 September 2024
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 42 (12) , 1055-1069
Metformin acts on miR-181a-5p/PAI-1 axis in stem cells providing new strategies for improving age-related osteogenic differentiation decline
A general decline in the osteogenic differentiation capacity of human bone marrow mesenchymal stem cells (hBMSCs) in the elderly is a clinical consensus, with diverse opinions on the mechanisms. Many studies have demonstrated that metformin (MF) significantly protects against osteoporosis and reduces fracture risk. However, the exact mechanism of this effect remains unclear. In this study, we found that the decreased miR-181a-5p expression triggered by MF treatment plays a critical role in recovering the osteogenic ability of aging hBMSCs (derived from elderly individuals). Notably, the miR-181a-5p expression in hBMSCs was significantly decreased with prolonged MF (1000 μM) treatment. Further investigation revealed that miR-181a-5p overexpression markedly impairs the osteogenic ability of hBMSCs, while miR-181a-5p inhibition reveals the opposite result. We also found that miR-181a-5p could suppress the protein translation process of plasminogen activator inhibitor-1 (PAI-1), as evidenced by luciferase assays and Western blots. Additionally, low PAI-1 levels were associated with diminished osteogenic ability, whereas high levels promoted it. These findings were further validated in human umbilical cord mesenchymal stem cells (hUCMSCs). Finally, our in vivo experiment with a bone defects rat model confirmed that the agomiR-181a-5p (long-lasting miR-181a-5p mimic) undermined bone defects recovery, while the antagomiR-181a-5p (long-lasting miR-181a-5p inhibitor) significantly promoted the bone defects recovery. In conclusion, we found that MF promotes bone tissue regeneration through the miR-181a-5p/PAI-1 axis by affecting MSC osteogenic ability, providing new strategies for the treatment of age-related bone regeneration disorders.
- Open Access
- 26 March 2024
- Published by Elsevier in Physics of Life Reviews
- Vol. 49, 77-94
Perception and response of skeleton to mechanical stress
- 26 March 2024
- Published by Elsevier in Physics of Life Reviews
- Vol. 49, 77-94
Open AccessPerception and response of skeleton to mechanical stress
- Open Access
- 28 December 2023
- Published by Spandidos Publications in Oncology Reports
- Vol. 51 (2) , 1-15
Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology andin vitroexperiments
Osteosarcomas are malignant bone tumors that typically originate in the epiphyses of the long bones of the extremities in adolescents. Asiatic acid has been reported to possess anti‑inflammatory, neuroprotective, antidiabetic, antitumor and antimicrobial activities. The present study used a combination of network pharmacological prediction and in vitro experimental validation to explore the potential pharmacological mechanism of asiatic acid against osteosarcoma. A total of 78 potential asiatic acid targets in osteosarcoma were identified using databases. Kyoto Encyclopedia of Genes and Genomes analysis indicated that the PI3K/AKT and MAPK signaling pathways are essential in the treatment of osteosarcoma with asiatic acid. Molecular docking revealed binding of asiatic acid to EGFR, Caspase‑3, ESR1, HSP90AA1, IL‑6 and SRC proteins. asiatic acid inhibited proliferation through G2/M cell cycle arrest in osteosarcoma cells. In addition, asiatic acid induced mitochondria‑dependent apoptosis as demonstrated by increases in Bax and VDAC1 expression, and a decrease in Bcl‑2 protein expression. The increased autophagosomes, increased LC3‑II/I ratios and decreased p62 expression in the treatment group indicated that asiatic acid triggered autophagy. In addition, asiatic acid decreased the levels of phosphorylated (p‑)PI3K/PI3K and p‑AKT/AKT, increased reactive oxygen species (ROS) and upregulated the levels of p‑ERK1/2/ERK1/2, p‑p38/p38 and p‑JNK/JNK in osteosarcoma cells. These results demonstrated that asiatic acid inhibited osteosarcoma cells proliferation by inhibiting PI3K/AKT and activating ROS/MAPK signaling pathways, suggesting asiatic acid is a potential agent against osteosarcoma.
- 28 December 2023
- Published by Spandidos Publications in Oncology Reports
- Vol. 51 (2) , 1-15
Open AccessExploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology andin vitroexperiments
Osteosarcomas are malignant bone tumors that typically originate in the epiphyses of the long bones of the extremities in adolescents. Asiatic acid has been reported to possess anti‑inflammatory, neuroprotective, antidiabetic, antitumor and antimicrobial activities. The present study used a combination of network pharmacological prediction and in vitro experimental validation to explore the potential pharmacological mechanism of asiatic acid against osteosarcoma. A total of 78 potential asiatic acid targets in osteosarcoma were identified using databases. Kyoto Encyclopedia of Genes and Genomes analysis indicated that the PI3K/AKT and MAPK signaling pathways are essential in the treatment of osteosarcoma with asiatic acid. Molecular docking revealed binding of asiatic acid to EGFR, Caspase‑3, ESR1, HSP90AA1, IL‑6 and SRC proteins. asiatic acid inhibited proliferation through G2/M cell cycle arrest in osteosarcoma cells. In addition, asiatic acid induced mitochondria‑dependent apoptosis as demonstrated by increases in Bax and VDAC1 expression, and a decrease in Bcl‑2 protein expression. The increased autophagosomes, increased LC3‑II/I ratios and decreased p62 expression in the treatment group indicated that asiatic acid triggered autophagy. In addition, asiatic acid decreased the levels of phosphorylated (p‑)PI3K/PI3K and p‑AKT/AKT, increased reactive oxygen species (ROS) and upregulated the levels of p‑ERK1/2/ERK1/2, p‑p38/p38 and p‑JNK/JNK in osteosarcoma cells. These results demonstrated that asiatic acid inhibited osteosarcoma cells proliferation by inhibiting PI3K/AKT and activating ROS/MAPK signaling pathways, suggesting asiatic acid is a potential agent against osteosarcoma.
- Open Access
- 27 December 2022
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 25 (2) , 1-9
CCL2 promotes proliferation, migration and angiogenesis through the MAPK/ERK1/2/MMP9, PI3K/AKT, Wnt/β‑catenin signaling pathways in HUVECs
Severe bone trauma can lead to poor or delayed bone healing and nonunion. Bone regeneration is based on the interaction between osteogenesis and angiogenesis. Angiogenesis serves a unique role in the repair and remodeling of bone defects. Monocyte chemoattractant protein‑1, also known as CC motif ligand 2 (CCL2), is a member of the CC motif chemokine family and was the first human chemokine to be revealed to be an effective chemokine of monocytes. However, its underlying mechanism in angiogenesis of bone defect repair remains to be elucidated. Therefore, the present study investigated the detailed mechanism by which CCL2 promoted angiogenesis in bone defects based on cell and animal model experiments. In the present study, CCL2 promoted proliferation, migration and tube formation in human umbilical vein endothelial cells (HUVECs) in a concentration‑dependent manner. Western blot analysis revealed that treatment of HUVECs with CCL2 upregulated the protein expression levels of rho‑associated coiled‑coil‑containing protein kinase (Rock)1, Rock2, N‑cadherin, c‑Myc and VEGFR2. Furthermore, CCL2 promoted the expression of MAPK/ERK1/2/MMP9, PI3K/AKT and Wnt/β‑catenin signaling pathway‑related proteins, which also demonstrated that CCL2 promoted these functions in HUVECs. Immunohistochemical staining of Sprague Dawley rat femurs following bone defects revealed that VEGF expression was positive in the newly formed bone area in each group, while the expression area of VEGF in the CCL2 addition group was markedly increased. Therefore, CCL2 is a potential therapeutic approach for bone defect repair and reconstruction through the mechanism of angiogenesis‑osteogenesis coupling.
- 27 December 2022
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 25 (2) , 1-9
Open AccessCCL2 promotes proliferation, migration and angiogenesis through the MAPK/ERK1/2/MMP9, PI3K/AKT, Wnt/β‑catenin signaling pathways in HUVECs
Severe bone trauma can lead to poor or delayed bone healing and nonunion. Bone regeneration is based on the interaction between osteogenesis and angiogenesis. Angiogenesis serves a unique role in the repair and remodeling of bone defects. Monocyte chemoattractant protein‑1, also known as CC motif ligand 2 (CCL2), is a member of the CC motif chemokine family and was the first human chemokine to be revealed to be an effective chemokine of monocytes. However, its underlying mechanism in angiogenesis of bone defect repair remains to be elucidated. Therefore, the present study investigated the detailed mechanism by which CCL2 promoted angiogenesis in bone defects based on cell and animal model experiments. In the present study, CCL2 promoted proliferation, migration and tube formation in human umbilical vein endothelial cells (HUVECs) in a concentration‑dependent manner. Western blot analysis revealed that treatment of HUVECs with CCL2 upregulated the protein expression levels of rho‑associated coiled‑coil‑containing protein kinase (Rock)1, Rock2, N‑cadherin, c‑Myc and VEGFR2. Furthermore, CCL2 promoted the expression of MAPK/ERK1/2/MMP9, PI3K/AKT and Wnt/β‑catenin signaling pathway‑related proteins, which also demonstrated that CCL2 promoted these functions in HUVECs. Immunohistochemical staining of Sprague Dawley rat femurs following bone defects revealed that VEGF expression was positive in the newly formed bone area in each group, while the expression area of VEGF in the CCL2 addition group was markedly increased. Therefore, CCL2 is a potential therapeutic approach for bone defect repair and reconstruction through the mechanism of angiogenesis‑osteogenesis coupling.
- Open Access
Lipid Metabolism in Cartilage Development, Degeneration, and Regeneration
Lipids affect cartilage growth, injury, and regeneration in diverse ways. Diet and metabolism have become increasingly important as the prevalence of obesity has risen. Proper lipid supplementation in the diet contributes to the preservation of cartilage function, whereas excessive lipid buildup is detrimental to cartilage. Lipid metabolic pathways can generate proinflammatory substances that are crucial to the development and management of osteoarthritis (OA). Lipid metabolism is a complicated metabolic process involving several regulatory systems, and lipid metabolites influence different features of cartilage. In this review, we examine the current knowledge about cartilage growth, degeneration, and regeneration processes, as well as the most recent research on the significance of lipids and their metabolism in cartilage, including the extracellular matrix and chondrocytes. An in-depth examination of the involvement of lipid metabolism in cartilage metabolism will provide insight into cartilage metabolism and lead to the development of new treatment techniques for metabolic cartilage damage.
Open AccessLipid Metabolism in Cartilage Development, Degeneration, and Regeneration
Lipids affect cartilage growth, injury, and regeneration in diverse ways. Diet and metabolism have become increasingly important as the prevalence of obesity has risen. Proper lipid supplementation in the diet contributes to the preservation of cartilage function, whereas excessive lipid buildup is detrimental to cartilage. Lipid metabolic pathways can generate proinflammatory substances that are crucial to the development and management of osteoarthritis (OA). Lipid metabolism is a complicated metabolic process involving several regulatory systems, and lipid metabolites influence different features of cartilage. In this review, we examine the current knowledge about cartilage growth, degeneration, and regeneration processes, as well as the most recent research on the significance of lipids and their metabolism in cartilage, including the extracellular matrix and chondrocytes. An in-depth examination of the involvement of lipid metabolism in cartilage metabolism will provide insight into cartilage metabolism and lead to the development of new treatment techniques for metabolic cartilage damage.
- Open Access
- 1 February 2022
- Published by Elsevier in Journal of Bone Oncology
- Vol. 33, 100415
Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways
- 1 February 2022
- Published by Elsevier in Journal of Bone Oncology
- Vol. 33, 100415
Open AccessBaicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways